A Phase 2 interventional study of Collagenase Clostridium Histolyticum Single Injection Technique and Collagenase Clostridium Histolyticum Multiple Injection Technique in Characteristics of Subcutaneous Tissue, sponsored by Endo Pharmaceuticals. Completed at 2 sites in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-12.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the histopathology of subcutaneous tissue isolated after single or multiple Collagenase Clostridium Histolyticum (CCH) injection techniques in adult female participants undergoing abdominoplasty.
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered 0.07 milligrams (mg) CCH subcutaneously using a single injection technique. Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -43 and -22. Area 2 was administered CCH on Day -14.
Drug: Collagenase Clostridium Histolyticum Single Injection Technique
Participants were administered 0.07 mg CCH subcutaneously using a single injection technique. Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -24 and -3. Area 2 was administered CCH on Day -3.
Drug: Collagenase Clostridium Histolyticum Single Injection Technique
Participants were administered 0.07 mg CCH subcutaneously using a single injection technique. Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -22 and -1. Area 2 was administered CCH on Day -1.
Drug: Collagenase Clostridium Histolyticum Single Injection Technique
Participants were administered 0.0653 mg CCH subcutaneously using a multiple injection technique. Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -43 and -22. Area 2 was administered CCH on Day -14.
Drug: Collagenase Clostridium Histolyticum Multiple Injection Technique
Participants were administered 0.0653 mg CCH subcutaneously using a multiple injection technique. Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -24 and -3. Area 2 was administered CCH on Day -3.
Drug: Collagenase Clostridium Histolyticum Multiple Injection Technique
Participants were administered 0.0653 mg CCH subcutaneously using a multiple injection technique. Each participant had 2 marked areas (Area 1 and Area 2) of the abdomen selected for injection. Area 1 was administered CCH on Days -22 and -1. Area 2 was administered CCH on Day -1.
Drug: Collagenase Clostridium Histolyticum Multiple Injection Technique
CCH was injected subcutaneously using a single injection technique. Dose per each administration was 0.07 mg.
Also known as: EN3835, CCH
CCH was injected subcutaneously using a multiple injection technique. Dose per each administration was 0.0653 mg.
Also known as: EN3835, CCH
Number of Participants With a Histologic Change in a Tissue Specimen That Was Injected With CCH
Tissue specimens isolated from participants undergoing an abdominoplasty procedure were observed for histopathological structure changes of tissues post treatment with CCH. The number of participants with a histologic change (as determined by the pathologist) in tissue dosed with CCH relative to control tissue (tissue not dosed with CCH) is reported.
Time frame: Up to collection of the excised abdominal tissue on Day 0 (day of abdominoplasty)
Number of Participants With a Histologic Change in a Tissue Specimen After 2 CCH Dose Injections Relative to a Tissue Specimen After 1 CCH Dose Injection
Tissue specimens isolated from participants undergoing an abdominoplasty procedure were observed for histopathological structure changes of tissues post treatment with CCH. The number of participants with a histologic change (as determined by the pathologist) in a tissue specimen injected with 2 CCH dose injections (Treatment Area 1) relative to 1 CCH dose injection (Treatment Area 2) is reported.
Time frame: Up to collection of the excised abdominal tissue on Day 0 (day of abdominoplasty)
Number of Participants With Anti-AUX-I and Anti-AUX-II Anti-Drug Antibodies (ADAs) After CCH Treatment
Serum samples were analyzed for anti-AUX-I clostridial class I collagenase of ADAs and anti-AUX-II Clostridial class II collagenase of ADAs. The number of participants who developed anti-AUX-I and anti-AUX-II ADAs (positive ADA result) are reported.
Time frame: End of Study (Day 28)
Number of Participants With Anti-AUX-I and Anti-AUX-II Neutralizing Antibodies (NAbs) After CCH Treatment
Serum samples were analyzed for anti-AUX-I and Anti-AUX-II Nabs. The number of participants who developed anti-AUX-I and Anti-AUX-II NAbs (positive NAb results) are reported. Neutralizing antibodies were only tested from ADA positive participants.
Time frame: End of Study (Day 28)
| Milestone | Group 1: Collagenase Clostridium Histolyticum (CCH) Single Injection Technique | Group 2: CCH Single Injection Technique | Group 3: CCH Single Injection Technique | Group 4: CCH Multiple Injection Technique | Group 5: CCH Multiple Injection Technique | Group 6: CCH Multiple Injection Technique |
|---|---|---|---|---|---|---|
| Started | 2 | 1 | 1 | 4 | 1 | 1 |
| Safety population | 2 | 1 | 1 | 4 | 1 | 1 |
| Evaluable population | 2 | 1 | 1 | 2 | 1 | 1 |
| Completed | 2 | 1 | 1 | 4 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Tissue specimens isolated from participants undergoing an abdominoplasty procedure were observed for histopathological structure changes of tissues post treatment with CCH. The number of participants with a histologic change (as determined by the pathologist) in tissue dosed with CCH relative to control tissue (tissue not dosed with CCH) is reported.
| Participants | Group 1: CCH Single Injection Technique | Group 2: CCH Single Injection Technique | Group 3: CCH Single Injection Technique | Group 4: CCH Multiple Injection Technique | Group 5: CCH Multiple Injection Technique | Group 6: CCH Multiple Injection Technique |
|---|---|---|---|---|---|---|
| Number of Participants With a Histologic Change in a Tissue Specimen That Was Injected With CCH | 2 | 1 | 1 | 2 | 1 | 1 |
Tissue specimens isolated from participants undergoing an abdominoplasty procedure were observed for histopathological structure changes of tissues post treatment with CCH. The number of participants with a histologic change (as determined by the pathologist) in a tissue specimen injected with 2 CCH dose injections (Treatment Area 1) relative to 1 CCH dose injection (Treatment Area 2) is reported.
| Participants | Group 1: CCH Single Injection Technique | Group 2: CCH Single Injection Technique | Group 3: CCH Single Injection Technique | Group 4: CCH Multiple Injection Technique | Group 5: CCH Multiple Injection Technique | Group 6: CCH Multiple Injection Technique |
|---|---|---|---|---|---|---|
| Number of Participants With a Histologic Change in a Tissue Specimen After 2 CCH Dose Injections Relative to a Tissue Specimen After 1 CCH Dose Injection | 2 | 1 | 1 | 2 | 1 | 1 |
Serum samples were analyzed for anti-AUX-I clostridial class I collagenase of ADAs and anti-AUX-II Clostridial class II collagenase of ADAs. The number of participants who developed anti-AUX-I and anti-AUX-II ADAs (positive ADA result) are reported.
| Participants | CCH Subcutaneous Injection |
|---|---|
| Anti-AUX-I ADAs | 9 |
| Anti-AUX-II ADAs | 5 |
Serum samples were analyzed for anti-AUX-I and Anti-AUX-II Nabs. The number of participants who developed anti-AUX-I and Anti-AUX-II NAbs (positive NAb results) are reported. Neutralizing antibodies were only tested from ADA positive participants.
| Participants | CCH Subcutaneous Injection |
|---|---|
| Anti-AUX-I NAbs | 7 |
| Anti-AUX-II NAbs | 3 |
Collected over From first injection (earliest dosing visit at Day -43) up to collection of the excised abdominal tissue on Day 0 (day of abdominoplasty) for CCH injection treatment and up to end of study (Day 28 post-abdominoplasty surgery follow-up visit). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: CCH Single Injection Technique | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Group 2: CCH Single Injection Technique | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Group 3: CCH Single Injection Technique | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Group 4: CCH Multiple Injection Technique | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Group 5: CCH Multiple Injection Technique | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Group 6: CCH Multiple Injection Technique | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Group 1: CCH Single Injection Technique | Group 2: CCH Single Injection Technique | Group 3: CCH Single Injection Technique | Group 4: CCH Multiple Injection Technique | Group 5: CCH Multiple Injection Technique | Group 6: CCH Multiple Injection Technique |
|---|---|---|---|---|---|---|
| Injection site bruisingGeneral disorders | 1/2 | 1/1 | 1/1 | 3/4 | 0/1 | 0/1 |
| Injection site painGeneral disorders | 2/2 | 0/1 | 0/1 | 4/4 | 1/1 | 1/1 |
| Injection site haemorrhageGeneral disorders | 2/2 | 0/1 | 0/1 | 1/4 | 0/1 | 0/1 |
| HypertensionVascular disorders | 1/2 | 0/1 | 0/1 | 0/4 | 0/1 | 1/1 |
| Abdominal herniaGastrointestinal disorders | 0/2 | 1/1 | 0/1 | 1/4 | 0/1 | 1/1 |
| HypoaesthesiaNervous system disorders | 1/2 | 1/1 | 1/1 | 4/4 | 1/1 | 1/1 |
| Post procedural swellingInjury, poisoning and procedural complications | 1/2 | 1/1 | 0/1 | 0/4 | 1/1 | 0/1 |
| Procedural painInjury, poisoning and procedural complications | 2/2 | 1/1 | 1/1 | 4/4 | 1/1 | 1/1 |
| EcchymosisSkin and subcutaneous tissue disorders | 2/2 | 1/1 | 1/1 | 3/4 | 1/1 | 1/1 |
| Postoperative wound infectionInjury, poisoning and procedural complications | 0/2 | 1/1 | 0/1 | 0/4 | 0/1 | 0/1 |
Safety Population: All participants who received at least 1 injection of study drug irrespective of the timing window of abdominoplasty. Baseline characteristics (demographic) data were combined for all participants to protect personally identifiable information (PII) of the participant and to reduce risk of participant identification in the small population size of the 2 arms/groups.
| Age, Continuous(years) | CCH Subcutaneous Injection |
|---|---|
| Mean | 44.1 ± 10.55 |
| Sex: Female, Male(Participants) | CCH Subcutaneous Injection |
|---|---|
| Female | 10 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | CCH Subcutaneous Injection |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 8 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | CCH Subcutaneous Injection |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Weight(Kg) | CCH Subcutaneous Injection |
|---|---|
| Mean | 71.31 ± 16.275 |
| Height(cm) | CCH Subcutaneous Injection |
|---|---|
| Mean | 164.47 ± 7.265 |
| BMI(kg/m^2) | CCH Subcutaneous Injection |
|---|---|
| Mean | 26.24 ± 4.460 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan
Ran from Dec 2019 to primary completion in Sep 2020, 9 months.
Results were first posted in Apr 2022, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase